Cancer risk is increased substantially in adult kidney transplant recipients, but the long-term risk of cancer in childhood recipients is unclear. Using the Australian and New Zealand Dialysis and Transplant Registry, the authors compared overall and site-specific incidences of cancer after transplantation in childhood recipients with population-based data by using standardized incidence ratios (SIRs). Among 1734 childhood recipients (median age 14 years, 57% male, 85% white), 289 (16.7%) developed cancer (196 nonmelanoma skin cancers, 143 nonskin cancers) over a median follow-up of 13.4 years. The 25-year cumulative incidences of any cancer were 27% (95% confidence intervals 24-30%), 20% (17-23%) for nonmelanoma skin cancer, and 14% (12-17%) for nonskin cancer (including melanoma). The SIR for nonskin cancer was 8.23 (95% CI 6.92-9.73), with the highest risk for posttransplant lymphoproliferative disease (SIR 45.80,) and cervical cancer (29.4, 95% CI 17.5-46.5). Increasing age at transplantation (adjusted hazard ratio [aHR] per year 1.10, 95% CI 1.06-1.14), white race (aHR 3.36, 95% CI 1.61-6.79), and having a functioning transplant (aHR 2.27, 95% CI 1.47-3.71) were risk factors for cancer. Cancer risk, particularly for virus-related cancers, is increased substantially after kidney transplantation during childhood.
Introduction
Cancer is an important and well-recognized complication after kidney transplantation in adults (1, 2) . The cumulative absolute risk of any cancer 20 years after transplantation is approximately 35%, corresponding to a relative increased risk of fourfold compared with the general population (3) (4) (5) . The excess risk is site specific, being higher for virus-related cancers such as posttransplant lymphoproliferative disorder (PTLD) and cervical cancer and lower for non-virus-and non-immune-related cancers, such as breast and bowel cancers (6) . Causal pathways are yet to be determined in detail but may be attributed to cumulative exposure to chronic immunosuppression, leading to loss of antitumor and antiviral immune surveillance (2, (6) (7) (8) .
Cancer risk in recipients who received a kidney transplant during childhood is less well defined. A single study of 231 children reported a 20-year cumulative cancer incidence of approximately 11% after transplantation, with nonmelanoma skin cancer as the most common (9) . Others have suggested PTLD is the most common cancer after kidney transplantation in children (10) (11) (12) (13) . Most previous studies are limited by their small sample size, relatively short follow-up periods, and sparse data on the risk of specific cancer types. Risk factors for cancer after kidney transplantation in childhood have not been explored for any cancer except PTLD.
The aims of this study were to determine the absolute and relative risks of cancer and the risk factors for the development of cancer in patients who received their first kidney transplants as children or adolescents.
Methods

Study population and setting
This long-term cohort study included all children and adolescents (younger than 20 years) who underwent kidney transplantation in Australian or New Zealand between January 1963 and December 2013. Patients with combined organ transplants (e.g. liver-kidney) and those who had a cancer before their first transplantation were excluded. Data were collected from the Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry, which prospectively collects data on all patients who commence renal replacement therapy in Australia and New Zealand (14) . 
Covariates of interest:
Outcomes:
The ANZDATA registry records all incident cancers (nonmelanoma skin and nonskin) of all renal transplant recipients. Incident cancers were defined as the first cancer diagnosed after transplantation. The treating nephrology team reports all nonskin cancers and the first skin squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) after transplantation. Prior work has validated the cancer reporting in ANZDATA against the statutory reporting Central Cancer Registry and found good concordance (15) . Diagnoses of incident cancers (C0-C97) were coded according to the International Classification of Diseases, Tenth Revision (ICD-10) for cancers (16) . Premalignant and in situ lesions were excluded. Non-Hodgkin's lymphoma (NHL) and PTLD were classified together as NHL/PTLD as there was insufficient information to distinguish between the two groups. Only malignant cases of PTLD are reported to ANZDATA.
Statistical analysis
Results were expressed as frequencies (percentages) for categorical data, mean (SD) for continuous normally distributed data, or median (interquartile range [IQR]) for continuous non-normally distributed data.
Nonskin cancer incidence was compared with the Australian Institute of Health and Welfare (AIHW) general population data from 1982 to 2010 by using standardized incidence ratios (SIRs). Cancer incidences (except nonmelanoma skin cancer) are collected by the AIHW from the Australian Cancer Database and reported in age categories of 5 years, stratified by sex, for each calendar year. In addition, the AIHW reports the age-and sex-stratified population for each year. The general population at risk for cancer, stratified by sex, was established by subtracting the number of people who had developed an incident cancer in any given year from the person-time for all subsequent years, divided into 5-year age categories. The expected nonskin cancer event rate was calculated based on the crude incidence in each age group. The ratios of the observed to the expected incidences of nonskin cancers were calculated by using the indirect age standardization method, and their 95% CIs were calculated by assuming a Poisson distribution. The excess risks of site-specific incident cancers with >10 cases were calculated by using the same method. The expected numbers of incident cases were calculated by multiplying the overall person-years at risk by the corresponding population cancer incidence. Person-years for the observed were counted from the time of transplantation to the time of death, loss to follow-up, end of study (December 31, 2013), or diagnosis, whichever came first.
For survival analyses, the follow-up period was defined from the time of transplantation to the time of first cancer diagnoses after transplantation. Those who did not develop cancer were censored at the time of death or end of study. A nonparametric estimation of the adjusted cumulative incidence function of cancer after transplantation was performed by using competing risk analysis. This considered the event of interest (i.e. cancer incidence) and other competing events (death). Anyone who did not experience the "event" (i.e. event free) was censored. The proportions free from incident cancers were calculated by using the Fine-Gray method, allowing for the competing event of death.
Univariable and multivariable Cox proportional hazard models assessed the risk factors for cancer development after transplantation. Variables that had an association with incident cancer at a p-value of <0.25 in the unadjusted analyses were included in the initial multivariable-adjusted analyses. In addition, sex, immunosuppression, and age at transplantation were included a priori in the final adjusted model because these variables have previously been shown to influence the risk of cancer after transplantation. Potential effect modification was tested between age, race, and sex by using two-way interaction terms. Transplant status (functioning transplant or receiving dialysis) was also assessed as a time-varying covariate. Given a time-varying covariate was included in the multivariable analyses, we did not account the other causes of death as competing events. Instead, participants were censored at the time of death. The proportional hazards assumptions of all Cox models were assessed by fitting time-dependent covariates in the multivariable models and plotting the Schoenfeld residuals. Model suitability was tested by using a stepwise backward elimination method to determine the optimal model. Data were structured by using Python 2.7, with the modules Pandas and NumPy. Data analysis were performed with SAS Studio (SAS Institute, Cary, NC), with p values <0.05 considered statistically significant.
Results
From 1963 to December 2013, 1748 children and adolescents received their first renal transplant. Fourteen children with cancer before their first transplantation were excluded, leaving 1734 children, of whom 576 (33%) received two or more subsequent kidney transplants. The median follow-up time was 13.4 years (IQR 5.4-23.5 years) with a total follow-up time of 26 220 patient-years.
Baseline characteristics: The baseline characteristics of the cohort are presented in Table 1 . The majority of recipients were transplanted in their teenage years and had congenital anomalies of the kidney and urinary tract.
Incidence of skin and nonskin cancers: There were 289 transplant recipients (16.7%, 95% CI 14.9-18.4%) who developed at least one cancer, with 196 incident nonmelanoma skin cancers and 143 incident nonskin cancers (including melanoma). There were 50 people who developed both an incident skin and nonskin cancer. Of the 289 first cancers of any cause, the majority (161 [56%]) occurred within the first graft period, 96 (33%) occurred during a subsequent graft, and only 32 developed with the patient receiving dialysis after a failed graft. After adjustment for the competing risk of death, the cumulative incidences of cancers at 25 years after first renal transplant were 27% (95% CI 24-30%) for all cancers, 20% (95% CI 17-23%) for nonmelanoma skin cancer, and 14% (95% CI 12-17%) for nonskin cancer ( Figure 1 ).
Incidence of site-specific cancer ( Table 2 ): The most common incident skin cancer type was SCC (n = 129, 7.4%, 95% CI 6.3-8.8%), followed by BCC (n = 67, 3.9%, 95% CI 3.1-4.9%). The most common nonskin cancer was NHL/PTLD (n = 40, 2.3%, 95% CI 1.7-3.1%), followed by cervical cancer (n = 18, 1.0%, 95% CI 0.7-1.7%). Proportion of total cases of nonmelanoma skin cancer or solid organ cancer for that site-specific cancer. (Table S1 and Figure S1 ).
Risk factors for nonmelanoma skin cancer and nonskin cancers were examined by using Cox regression (Tables S2 and S3 Incidence compared with the general population: After a median follow-up time of 13.4 years, 143 incident nonskin cancers were observed in the transplanted population compared with an expected number of 17.4 (SIR = 8.23, 95% CI 6.9-9.7). The risk was elevated equally for males and females (Table 3) The risk of cancer for the transplant cohort was similar to that in the general population who were 25-30 years older. For example, the cancer risk of a 20-year-old kidney transplant recipient was similar to that of people aged 50 without kidney disease (297/100,000, compared with 219-347/100,000, respectively). The excess risk compared with that of the general population was not constant but varied with age, with the risk declining with increasing age (Figure 3 ). 
Discussion
Cancer is a common complication after kidney transplantation during childhood. Accounting for the competing risks of death, more than one-fourth of childhood recipients are expected to develop cancer by 25 years after transplantation. Nonmelanoma skin cancers are the most common cancer type, and cancers related to viruses, such as NHL, PTLD, and cervical cancer are heavily overrepresented. Compared with the general population, childhood kidney transplant recipients experienced around an eightfold increased risk of nonskin cancer.
The median time to cancer development varied by cancer type. For instance, NHL and PTLD presented early, within 7 years after transplantation, while all other cancer types occurred around 15-17 years after the first transplantation. With the exception of NHL and PTLD, most other cancers occurred after the child had transitioned to adult care. Increasing age at first transplantation, having a functioning transplant (a proxy for taking immunosuppression), and white race were independent risk factors for cancer development after transplantation.
The cumulative incidence of cancer observed in this Australian/New Zealand cohort was higher than in most other pediatric reports (10, 11, (17) (18) (19) (20) . In Europe, the reported cumulative incidence of cancers varied between 7% at 10 years and 18% at 25 years after kidney transplantation in childhood (9, 12) . The higher rates of cancer observed in Australia and New Zealand may have been attributable to risk factors, such as the increased exposure to ultraviolet light. Latitude of residence closer to the equator (and, hence, increased ultraviolet light exposure) was associated with increased risk of nonmelanoma skin cancer in this cohort. Alternately, the larger cohort size and longer follow-up may have provided improved precision of the estimates of cancer risk. Transplant era did not have any significant effects on cancer risk after transplantation.
While the incidence of cancer in this cohort was higher than that in other pediatric studies, it remains markedly lower than that in adult kidney transplant recipients (4, 21) . Previous studies reported a higher incidence of cancer, with a 20-year cumulative incidence of cancer (including nonmelanoma skin cancer) approaching as high as 60% in adult transplant recipients (3, 17, 18, 22) . The lower cumulative incidence of cancer in those who received a kidney transplant during childhood was expected, as increasing age at transplantation has been associated with increased cancer risk (3, (21) (22) (23) . This study further confirms findings from previous observational studies. For every 1-year increase in age at transplantation, the overall risk of cancer increased by at least 10%. The consistent increase in the relative and absolute risk of cancer over time and across all age groups suggest that age alone is not the only risk factor for cancer but may be directly associated with the long-term exposure to immunosuppression.
This cohort had an excess risk of cancer by eight times that of the general population, which is higher than reports from previous adult studies (1, 5, 6) . Previous findings from the ANZDATA registry show a threefold increased risk for all solid organ cancers in the adult kidney transplant population compared with the age-and sex-matched population during a similar era (3). The SIR of cancer for childhood kidney transplant recipients is higher than that for adult kidney transplant recipients, as in childhood and early adulthood the general population is at a very low risk of most types of cancer (24) .The cumulative effects of longterm immunosuppression and decreased antiviral activity may have accounted for the sizable differences in cancer risk between the transplant population and their healthy peers. This study extends prior knowledge by showing that for childhood recipients of a kidney transplant, a functioning transplant is a significant risk factor for nonmelanoma skin cancer development, with an adjusted increased risk of at least twofold compared with receiving dialysis after a failed graft. White race and living closer to the equator were associated with increased risk of nonmelanoma skin cancer. The higher cancer incidence observed in the transplanted population may also be partially explained by early detection bias. Transplant recipients may undergo frequent medical assessments and cancer screening, thus resulting in an overestimation of cancer incidence compared with the general population.
Previous studies in the adult transplant population have shown that virus-related cancers are common after transplantation (2, 5, 6) . Viruses, such as human papillomavirus (HPV) and EBV, are well-established risk factors for multiple tumor types. HPV may be associated with skin SCC and is causal for tongue, mouth, anal, cervical, and penile cancer (25, 26) . EBV also plays a causative role in Hodgkin lymphoma and NHL/PTLD (26) . This study confirms and extends the previous observations, showing that the most common site-specific cancers in those transplanted in childhood were cancers caused or possibly caused by viruses, such as nonmelanoma skin cancer (predominantly SCC), NHL, PTLD, and cervical cancer. Consistent with other studies, virus-associated cancers such NHL and PTLD occurred at higher rates than other non-virusrelated cancer types (11, 27) .
Given that HPV infection is potentially preventable, the HPV vaccine may provide a unique opportunity for disease prevention in high-risk groups, such as those transplanted during early childhood. The magnitude of the increased risk for cervical cancers in women who had undergone transplantation as a child, with reference to the general population, was substantially higher than that of adult female transplant recipients (6) . This implies that the cumulative risk of immunosuppression may have had an impact on immune system cancer surveillance and antiviral efficacy. In addition, women who are transplanted in childhood are much more likely to be immunosuppressed when they first encounter HPV and thus less likely to clear the virus and more likely to develop cancer (28, 29) . With the availability of the HPV vaccine, protection of HPV-related cancer through herd immunization of all at-risk preteens before exposure to the virus is crucial to prevent cancer development after transplantation.
The time to first cancer in this study was similar to other times reported in pediatric studies with similar follow-up times (10) (11) (12) 19) . NHL and PTLD developed early (within a median of 7 years) after transplantation and at a much younger age (median age 18 years) compared with other cancer types. The relatively short time to cancer suggested that childhood kidney transplant recipients experienced cancer as young adults or, particularly for PTLD, even while still in pediatric care.
This study was strengthened by its long follow-up time, large sample size, and completeness of cancer records within the ANZDATA registry. The reliability and comprehensive nature of cancer data collection in ANZDATA meant that selection and ascertainment biases were minimized (15) . Incidence was also calculated accounting for the competing event of death. This study may have several weaknesses. The nature of a registry-based analysis suggested potential residual confounding and selection, detection, and coding biases may have occurred, particularly for nonmelanocytic skin cancers. Inability to inspect patient records meant that potentially confounding data such as in-depth information on comorbidities, medications, and environmental exposures was unable to be elicited. Drug dosing information was not routinely collected within the ANZDATA registry. As such, the impact of the cumulative dose of immunosuppressive agents and cancer risk after transplantation were unable to be assessed. In addition, data on the treatment of rejection have been reliably collected only since 1997, so the effect of rejection and its treatment on cancer risk were unable to be explored. Other than for nonmelanoma skin cancer, risk factors for specific cancer types could not be examined due to the small numbers of events in each group. EBVpositive donor-to-EBV-negative recipient confers an increased risk of PTLD, but donor EBV data were mostly incomplete and so the association between EBV and PTLD was unable to be examined. The risk of PTLD and PTLD-related mortality are the subjects of our future research.
In conclusion, cancer occurs commonly after kidney transplantation in childhood and adolescence. Similar to adult kidney transplant recipients, nonmelanoma skin cancers and virus-related cancers predominated and occurred much more commonly compared with the general population. NHL/PTLD occurred earlier than all other cancer types. Increasing age at transplantation, white race, and having a functioning transplant were associated with increased risk of cancer. Given the high rates of virus-related cancer, such as cervical cancers, interventions such as HPV vaccine may potentially reduce the future burden of vaccine-preventable cancers. 
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